Statement: Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial.
Primary_evidence: Inclusion Criteria:   Postmenopausal women, Stage III or axillary node positive   Currently disease free of breast cancer and other invasive malignancies at the time of registration   No concurrent use of bisphosphonates Exclusion Criteria: Metastatic disease
Secondary_evidence: Inclusion Criteria:   Pathologically confirmed HER2-positive MBC   Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery   Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment   Stable systemic disease   Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1   LVEF at least 50%   Adequate hematologic, renal, and hepatic function   Life expectancy more than 12 weeks Exclusion Criteria:   Progression of systemic disease at Screening   Leptomeningeal disease   History of intolerance or hypersensitivity to study drug   Use of certain investigational therapies within 21 days prior to enrollment   Current anthracycline use   Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use   Active infection   Pregnant or lactating women   Significant history or risk of cardiac disease   Symptomatic intrinsic lung disease or lung involvement   History of other malignancy within the last 5 years